November 24, 2015
Presage appoints two new directors
Presage Biosciences, an oncology company has appointed Tachi Yamada and Christoph Lengauer to its board of directors.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 24, 2015
Lilly’s lung cancer drug in combo with gemcitabine and cisplatin gets FDA’s OK
Eli Lilly has gotten the U.S. Food and Drug Administration (FDA) approval for cancer drug Portrazza, which comes in a form of injection for intravenous use, 800 mg/50 mL, in combination with gemcitabine and cisplatin.
November 24, 2015
Lupin gets a go-ahead to market Blisovi – generic version Warner Chilcott’s Loestrin tablets – in U.S.
US FDA has given Lupin a go to market Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets.
November 24, 2015
Pfizer to buy Allergan in $160 billion deal
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion (£106 billion) to slash its U.S. tax bill, rekindling a fierce political debate over the financial manoeuvre.
November 24, 2015
Tiziana Life Sciences places banker to its Board
Tiziana Life Sciences plc, the clinical stage biotechnology company focused on oncology and immunology related drugs, has appointed a banker Willy Simon as a non-executive director.
November 24, 2015
Futura Medical’s two painkillers cleared path for Europe
Futura Medical, a transdermal technology specialist, has received by an European regulator clarity on the regulatory pathways for its two topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen).
November 24, 2015
Abzena buys US-based contract chemistry specialist TCRS for $15M
Abzena plc will buy Philadelphia-based The Chemistry Research Solution LLC (TCRS), a specialist contract chemistry and bioconjugation company, specialized in producing and analyzing antibody drug conjugates (DACs), for $15 million
November 24, 2015
Advanced Oncotherapy names CERN’s Stephen Myers new Chairman of ADAM
Advanced Oncotherapy, the developer of proton therapy systems for cancer treatment, has appointed Professor Stephen Myers OBE, Head of Medical Applications at CERN, as Executive Chairman of its subsidiary ADAM S.A.
November 24, 2015
Texas ADAP adds Turing’s Daraprim to formulary
The Texas AIDS Drug Assistance Program (ADAP) Advisory Committee has added Daraprim to its formulary, making the medicine more accessible and affordable to AIDS patients across the state.
A privately-held biopharmaceutical company Turing Pharmaceuticals said Monday that Daraprim will be sold to the program for $1.00 per 100-count bottle.
November 24, 2015
Novartis’ heart failure tablet Entresto available in EU
European Commission has approved Switzerland-based Novartis’ Entresto tablets for treating adult patients with symptomatic chronic heart failure with reduced ejection fraction.